Organ-on-a-Chip in Fibrosis: Promise and Limitations

Lead: With the enactment of the FDA Modernization Act 2.0 (signed December 2022; effective 2023), the statutory requirement for animal testing in new drug applications was broadened to permit non-animal alternatives — including Organ-on-a-Chip / MPS, organoids, and AI/ML-based approaches — rather than mandating animal data absolutely (Adashi EY, Am J Med 2023, PMID 37080328; Stewart A, Drug Discov Today 2023, PMID 36690176). In regulatory practice, however, acceptance remains case-by-case under a weight-of-evidence framework that depends on drug class, indication, risk profile, and the overall data package — MPS does not yet operate as a standalone replacement for animal toxicology. The FDA has continued to expand this framework, releasing a Roadmap to Reducing Animal Testing in Preclinical Safety Studies in April 2025 and a CDER draft guidance on validating New Approach Methodologies (NAMs) in March 2026, though formal acceptance still proceeds case-by-case. This legislative shift has accelerated interest in Organ-on-a-Chip (Microphysiological Systems: MPS). But can a complex, multi-cellular pathology like "fibrosis" really be replicated on a plastic chip? In this article, we provide a balanced, scientific review of what Organ-on-a-Chip can do (Potential) and what it cannot yet do (Limitations) in the context of fibrosis drug discovery.

Key Takeaways

• Why MPS is gaining traction post-FDA Modernization Act
• Current use cases in Liver and Lung fibrosis
• The "Hybrid Strategy" combining MPS and Animal Models

---

1. What is Organ-on-a-Chip (MPS)?

Organ-on-a-Chip (Microphysiological Systems: MPS) refers to microfluidic devices lined with living human cells that mimic the physiological functions and mechanics of human organs. Unlike traditional Petri dishes (2D culture), these systems incorporate "Flow" (fluid dynamics) and "3D Structure," allowing for more predictive in vitro modeling.

---

2. Applications in Fibrosis Research

Fibrosis involves a cascade of "Inflammation → Myofibroblast Activation → ECM Accumulation." Chip technology is advancing to capture these steps in specific organs.

Liver-on-a-Chip (MASH/Fibrosis)

Platforms like Emulate or MIMETAS co-culture hepatocytes, Kupffer cells, and Stellate Cells (HSC).

• Advantage: Using human cells reduces the species-difference gap between rodents and humans — not a complete bypass, since donor variability, maturation state, and culture conditions remain separate sources of bias.
• Validation: Can reproduce fatty acid-induced steatosis and TGF-β driven HSC activation (α-SMA expression), making it useful for screening anti-fibrotic compound efficacy.

Lung-on-a-Chip (IPF/Lung Fibrosis)

Co-cultures alveolar epithelial cells and endothelial cells across a porous membrane, creating an Air-Liquid Interface. A key feature is the ability to enable mechanical stretching to mimic "Breathing" motions.

• Validation: Can evaluate epithelial barrier disruption and marker checks induced by bleomycin or other stressors.

---

3. The Comparison: In Vivo vs. On-Chip

Where do they stand today?

Metric	Animal Models (In Vivo)	Organ-on-a-Chip (MPS)
System Complexity	Complete Interactions with immune system, nervous system, microbiome.	Partial Co-culture of key cell types only. Lacks systemic context.
Pathology Replication	Complex Can model tissue architecture destruction and immune cell recruitment.	Early Events Good for analyzing cell activation and factor release, but poor at remodeling tissue architecture.
Throughput	Low - Medium (Months per study)	Platform-dependent (Automated parallel MPS platforms have reported medium-to-high throughput, but many chip systems remain lower-throughput than conventional 2D well-plate assays)
Relevance	Species gap (Rodent ≠ Human)	Reduced species gap (uses human cells; donor variability, maturation state, and culture conditions remain)
Cost	High (Housing, Management)	High setup; running costs vary widely by platform, automation, and analytics (not readily generalizable).

---

4. The Current Limitations

While powerful, Organ-on-a-Chip is not yet a complete replacement for animal testing in fibrosis research due to:

1. Lack of Systemic Immune Response

Fibrosis is driven by the recruitment of bone-marrow derived inflammatory cells and systemic cytokine networks. Closed chip systems struggle to replicate this dynamic recruitment.

2. Time Scale of Chronic Disease

Fibrosis in humans and animals develops over weeks to months. Chips typically run for days to weeks. Mimicking the slow, irreversible remodeling and tissue hardening of chronic fibrosis remains a challenge.

---

5. FAQ

Q: Will animal testing disappear completely? A: In the long term, the goal is reduction. Currently, we are in a phase of Reduction and partial Replacement. For evaluating systemic safety and complex chronic efficacy, animal models remain essential.

Q: Do regulators accept Chip data? A: The FDA positions MPS / Organ-on-a-Chip data as supportive evidence under a weight-of-evidence framework, evaluated on a case-by-case basis (Zushin PJ, J Clin Invest 2023, PMID 37909337; Stewart A, Drug Discov Today 2023, PMID 36690176). It is not yet accepted as a standalone replacement for safety (toxicology) testing; sponsors are expected to align with regulators in advance, with the acceptable scope depending on drug class, indication, and risk profile.

---

6. The Proposal: The "Hybrid Strategy"

We advocate not for choosing one over the other, but for a Hybrid Strategy.

1. High-Throughput Screening (HTS): Use Organ-on-a-Chip to screen compound libraries (hundreds to thousands of compounds, depending on platform throughput) against human cells to filter out toxic hits and identify potential anti-fibrotic candidates.
2. Systemic Validation: Take only the promising Hits into Animal Models to verify efficacy, PK/PD, and systemic safety in a living organism.

This complementary approach leverages the strengths of both tools to accelerate reliable drug discovery.

---

Further Reading

• Comparing Traditional Models
  • MASH Model Selection Guide: GAN vs CDA vs STAM
• Cutting-Edge Evaluation
  • AI Pathology for Objective Fibrosis Scoring
• Foundational Methods
  • Quantitative Fibrosis Assessment: Hydroxyproline & Sirius Red

---

References

Organ-on-a-Chip Foundational Literature

1. Jang KJ, et al. Liver-chip modeling of non-alcoholic steatohepatitis. EBioMedicine. 2019;46:297-311. PubMed PMID 31399373
2. Huh D, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328(5986):1662-1668. PubMed PMID 20576885
3. Low LA, et al. Organs-on-chips: into the next decade. Nat Rev Drug Discov. 2021;20(5):345-361. PubMed PMID 32913334

FDA Modernization Act 2.0 / NAMs Commentary

4. Adashi EY, O'Mahony DP, Cohen IG. The FDA Modernization Act 2.0: Drug Testing in Animals Is Rendered Optional. Am J Med. 2023;136(9):853-854. PubMed PMID 37080328
5. Zushin PH, Mukherjee S, Wu JC. FDA Modernization Act 2.0: transitioning beyond animal models with human cells, organoids, and AI/ML-based approaches. J Clin Invest. 2023;133(21):e175824. PubMed PMID 37909337
6. Stewart A, et al. The FDA modernisation act 2.0: Bringing non-animal technologies to the regulatory table. Drug Discov Today. 2023;28(4):103496. PubMed PMID 36690176